Overview

Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

This study will test the activity of single-agent EC145 and the combination of EC145 plus docetaxel against the current standard docetaxel in second line Non Small Cell Lung Cancer (NSCLC) (adenocarcinoma, squamous, adenosquamous or adenocarcinoma with other NSCLC variants of the lung) in participants with all target lesions expressing the folate receptor [FR(++)].

Phase:

Phase 2

Details

Lead Sponsor:

Endocyte

Treatments:

Docetaxel
Folic Acid
Vinca Alkaloids